In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4856-4861

  Vidaillac, Céline ^a,b   Benichou, Lothaire ^a   Duval, Raphaël E ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; COTRIMOXAZOLE; TRIMETHOPRIM; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BACTERIUM ISOLATE; BROTH DILUTION; CHECKERBOARD ASSAY; CONTROLLED STUDY; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PSEUDOMONAS AERUGINOSA; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VANCOMYCIN;

EID: 84865438542     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05996-11     Document Type: Article

References (26)

1. Adams MD, et al. 2009. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 53:3628-3634.
2. Antoniadou A, et al. 2007. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J. Antimicrob. Chemother. 59:786-790. (Pubitemid 47073420)
3. Bercot B, Poirel L, Dortet L, Nordmann P. 2011. In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae. J. Antimicrob. Chemother. 66:2295-2297.
4. Bergen PJ, et al. 2011. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob. Agents Chemother. 55:5134-5142.
5. Bergen PJ, et al. 2011. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 55:5685-5695.
6. Bratu S, et al. 2005. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 49:3018-3020. (Pubitemid 40917631)
7. .Bryson V, Szybalski W. 1952. Microbial selection. Science 116:45-51.
8. Champlin FR, Gilleland HE, Jr, Conrad RS. 1983. Conversion of phospholipids to free fatty acids in response to acquisition of polymyxin resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 24: 5-9. (Pubitemid 13076170)
9. Chiang WC, Pamp SJ, Nilsson M, Givskov M, Tolker-Nielsen T. 2012. The metabolically active subpopulation in Pseudomonas aeruginosa biofilms survives exposure to membrane-targeting antimicrobials via distinct molecular mechanisms. FEMS Immunol. Med. Microbiol. 65:245-256.
10. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI, Wayne, PA.
11. Conrad RS, Gilleland HE, Jr. 1981. Lipid alterations in cell envelopes of polymyxin-resistant Pseudomonas aeruginosa isolates. J. Bacteriol. 148:487-497. (Pubitemid 12218750)
12. Eliopoulos GM, Moellering RC. 1991. Antimicrobial combinations, p 432-492. In LorianV(ed), Antibiotics in laboratory medicine. Williams & Wilkins Co., Baltimore, MD.
13. Giacometti A, Cirioni O, Barchiesi F, Fortuna M, Scalise G. 1999. In vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 44:641-645. (Pubitemid 29532842)
14. Gordon NC, Png K, Wareham DW. 2010. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob. Agents Chemother. 54:5316-5322.
15. Hornsey M, Wareham DW. 2011. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 55:3534-3537.
16. Reference deleted.
17. Li J, et al. 2007. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin. Infect. Dis. 45:594-598. (Pubitemid 47328640)
18. Li J, et al. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
19. Li J, et al. 2010. Targeting multidrug-resistant Pseudomonas aeruginosa: pharmacodynamics of the combination of colistin and ciprofloxacin, abstr P1608. In Prog. 20th Eur. Congr. Clin. Microbiol. Infect. Dis. April 2010, Vienna, Austria.
20. Li J, et al. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50:2946-2950. (Pubitemid 44396396)
21. Nordmann P, Cuzon G, Naas T. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228-236.
22. Simmons NA. 1970. Colistin, sulphamethoxazole, and trimethoprim in synergy against Gram-negative bacteria. J. Clin. Pathol. 23:757-764.
23. Soon RL, et al. 2011. Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatment. J. Antimicrob. Chemother. 66:126-133.
24. Suh JY, et al. 2010. Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea. Antimicrob. Agents Chemother. 54:560-562.
25. Vuorio R, Vaara M. 1992. The lipid A biosynthesis mutation lpxA2 of Escherichia coli results in drastic antibiotic supersusceptibility. Antimicrob. Agents Chemother. 36:826-829.
26. Wareham DW, Gordon NC, Hornsey M. 2011. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 66:1047-1051.